0032 Metabolomic Profile of Excessive Daytime Sleepiness in the Hispanic Community Health Study/Study of Latinos
Tariq Faquih,Bing Yu,Robert Kaplan,Carmen Isasi,Susan Redline,Tamar Sofer,Heming Wang
DOI: https://doi.org/10.1093/sleep/zsae067.0032
IF: 6.313
2024-04-20
SLEEP
Abstract:Abstract Introduction Excessive daytime sleepiness (EDS) is a prevalent condition estimated to affect up to 33% of the United States population. EDS is a heterogeneous and complex symptom of various sleep disorders, insufficient sleep, and other chronic conditions and medications. EDS has also been associated with increased risk of cardiovascular and neuropsychiatric diseases, potentially through bidirectional causal pathways. In this study, we used metabolomic measurements in 6071 individuals from the Hispanic Community Health Study/Study of Latinos to elucidate the metabolomic factors associated with EDS. Methods EDS was assessed using the Epworth Sleepiness Score (a 24-point scale) at baseline (2008), continuously modeled. Metabolomics (877 metabolites) were quantified using the Metabolon platform—from blood assayed at baseline—and were log scaled. Our primary and sex stratified models adjusted for age, body mass index, ethnicity, recruitment center, alcohol, smoking, and physical activity. Secondary analysis further adjusted for insomnia, sleep duration, and sleep apnea. Significance threshold was set to 0.00013 to account for multiple testing. Finally, the interplay between metabolites, pathways, and genes was investigated through network and pathway enrichment analyses. Results Levels of seven metabolite were each associated with a decrease of the sleepiness score by approximately 0.4 points per one log unit increase in metabolite levels. Those metabolites were primarily categorized as fatty acids (Eicosadienoic acid, Docosadienoate), steroids (Pregnenolone sulphate, Tetrahydrocortisol-glucuronide), along with a sphingomyelin and two uncharacterized metabolites. Sex stratified analysis identified three additional metabolites associated with EDS in men: Tyramine O-sulfate and two phosphatidylcholines. Tyramine O-sulfate was particularly associated with an increased sleepiness score by 0.5 per log unit; with attenuation after adjusting for sleep traits. Network and pathway enrichment analysis indicated that changes in pathways related to cortisol metabolism, hormonal steroid metabolism, and melatonin metabolism were linked to EDS. Conclusion These results suggest that a combination of metabolomic factors, representing diet and steroid hormonal pathways dietary related metabolites, and some genetic factors contributes to the metabolic profile of EDS. Some associations appeared independent of common sleep disorders while a male-specific association was driven by sleep disturbances (insomnia). Support (if any) NIH R01HL153814 (to H.W.), R01HL161012 (to T.S.), and R35HL135818 (to SR).
neurosciences,clinical neurology